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Abstract
Background: Autoantibodies against self-antigens have been associated not only with autoimmune diseases, but
also with cancer and are even found in healthy individuals. The mechanism causing the autoantibody response
remains elusive for the majority of the immunogenic antigens. To deepen the understanding of autoantibody
responses, we ask whether natural-occurring, autoimmunity-associated and tumor-associated antigens have
structural or biological features related to the immune response. To this end, we have carried out the most
comprehensive in-silicio study of different groups of autoantigens including large antigen sets identified by our
groups combined with publicly available antigen sets.
Results: We found evidence for an enrichment of genes with a larger exon length increasing the probability of
the occurrence of potential immunogenic features such as mutations, SNPs, immunogenic sequence patterns and
structural epitopes, or alternative splicing events. While SNPs seem to play a more central role in autoimmunity,
somatic mutations seem to be stronger enriched in tumor-associated antigens. In addition, antigens of
autoimmune diseases are different from other antigen sets in that they appear preferentially secreted, have
frequently an extracellular location, and they are enriched in pathways associated with the immune system.
Furthermore, for autoantibodies in general, we found enrichment of sequence-based properties including coiled-
coils motifs, ELR motifs, and Zinc finger DNA-binding motifs. Moreover, we found enrichment of proteins binding
to proteins or nucleic acids including RNA and enrichment of proteins that are part of ribosome or spliceosome.
Both, homologies to proteins of other species and an enrichment of ancient protein domains indicate that
immunogenic proteins are evolutionary conserved and that mimicry might play a central role.
Conclusions: Our results provide evidence that proteins which i) are evolutionary conserved, ii) show specific
sequence motifs, and iii) are part of cellular structures show an increased likelihood to become autoimmunogenic.
Background
The generation of autoantibodies against self-antigens is
a common phenomenon in humans. Autoantibodies have
been directly associated with the pathophysiology of
some diseases most prominently with autoimmune dis-
eases. They also appear to occur in the context of many
o t h e rd i s e a s e sa sc a n c e ro rh a v ee v e nb e e nr e p o r t e di n
apparently healthy individuals. The meaning of these
autoantibodies is not understood and especially the
underlying mechanism eliciting an autoantibody response
remains elusive for the majority of the immunogenic
antigens. For the purpose of systematization, we differ-
entiate between natural-occurring, autoimmunity-asso-
ciated and tumor-associated antigens (HAGs, AAGs and
TAGs, respectively). One has to be aware that this group-
ing may be somewhat arbitrary since many antigens seem
to appear in more than one of the proposed groups.
Instead of allocating single antigens to a specific group of
diseases and even to a specific disease, it appears more
appropriate to allocate seroreactivity patterns, e.g. the
reactivity of multiple autoantibodies to a disease or group
of diseases. This idea is strongly supported by identifica-
tion of autoantibody reactivity patterns, also addressed as
autoantibody signatures that a r eh i g h l ys p e c i f i cf o rv a r -
ious cancers and some non-cancer diseases as shown by
us and others [1-10]. Provided that the identity of tumor
associated antigens mirrors deregulated pathways of a
specific cancer as recently suggested [11], autoantibody
signatures against tumor antigens might provide insight
into many of the deregulated pathways in cancer. * Correspondence: cbackes@bioinf.uni-sb.de
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become immunogenic including mutations, alternative
splicing, post-translational modifications, deregulated
apoptotic or necrotic processes, expression of fetal pro-
teins in adult tissue, single nucleotide polymorphisms
(SNPs), differential cellular localization and overexpression
[12-14]. For almost all antigens, the underlying reason for
their immunogenicity has not yet been elucidated. The
cause of immunogenicity may be rather complex as shown
for the tumor suppressor protein p53. Mutations in p53
have been identified for several cancers and other diseases.
In patients with rheumatoid arthritis, somatic mutations
of p53 are commonly found, whereas p53 antibodies were
only rarely detected in sera or synovial fluids [15]. In con-
trast, autoantibodies against p53 are detected in 4 - 30% of
sera of patients with various types of cancers [16], but only
20-40% of the patients with p53 mutations have autoanti-
bodies against p53. These autoantibodies recognize both
mutated and wild-type p53 [17]. While the mutations are
located in the central protein, the epitopes of the anti-p53
antibodies mostly map in the highly glycosylated amino-
and carboxy-terminal ends of the protein [18]. The muta-
tion causes a structural change in the p53 protein that
results in an increased half-life of the protein. The pro-
longed half-life of the mutated protein and the resulting
accumulation of p53 in the cell is likely a prerequisite for
its immunogenicity rather than the structural changes
caused by the mutation itself.
Besides mutations, the overexpression of fetal proteins
in cancer might also elicit an immune response. This is
due to the absence of fetal proteins during the time,
when the immune system is developing tolerance
against self-antigens. This seems to hold true for the
cancer-testis antigen NY-ESO-1, that was originally
identified as TAG in esophageal squamous cell carci-
noma. It is also expressed in several other cancers, e.g.
breast cancer, melanoma or prostate cancer [19].
Another interesting hypothesis is that alterated alter-
native splicing might play a central role in autoimmu-
nity. Ng et al. analyzed the extent of alternative splicing
in known self-proteins with an association to autoim-
mune diseases and compared them to randomly selected
human proteins [14]. They found an increased amount
of alternative splicing in the autoantigen transcripts and
in addition an increased noncanonical alternative spli-
cing, leading to the hypothesis that the generation of
untolerized epitopes may be responsible for the autoim-
mune response. The proposed “stimulation-responsive
splicing” model [20] refined this hypothesis by illustrat-
ing how alternative splicing of autoantigen and self-
tumor antigen mRNAs in response to stimuli may lead
to aberrant expression of antigen isoforms that present
novel untolerized epitopes generated by inclusion or
depletion of exons.
Alteration in the processes of apoptosis and necrosis
can also be associated with the generation of autoanti-
bodies. During apoptosis, antigen clusters are found in
apoptotic blebs, which are believed to be a major source
of intracellular autoantigens in autoimmune diseases
[21]. Some autoimmune diseases, e.g. systemic lupus
erythematosus (SLE), show an impaired uptake of apop-
totic cells into macrophages resulting in an accumula-
tion of dying cells [22]. These cells release so-called
danger signals that can trigger an increased immune
response [23]. Due to their prolonged presence in the
system, these cells might undergo secondary processes
including secondary necrosis as well as massive cell-
death related modifications. Antigens may be affected by
oxidation, hyperphosphorylation or aberrant cleavage, e.
g. through caspases and granzyme B [24-27].
Two processes have to be taken into account when
elucidating common features of autoantigens, epitope
spreading and molecular mimicry. Epitope spreading
refers to a model where an immune response is initiated
through an immunodominant epitope, while later on the
response expands to other neighboring epitopes in the
same protein [28,29]. This model has been confirmed
for autoimmune diseases as well as for animal models of
immunization [30]. Molecular mimicry describes a
mechanism in which structurally-related epitopes in dif-
ferent molecules induce the generation of cross-reactive
antibodies as described for autoimmune diseases that
were triggered by pathogen infection [31]. Molecular
mimicry can be perceived as a form of intermolecular
epitope spreading [32].
The present data strongly indicate that autoantigens
become immunogenic for various reasons in different
diseases. The generation of autoantibody repertoires is a
multifactor process involving aberrant expression of pro-
teins or protein structures combined with aberrant cell
death procedures and clearance of these cells by the
immune system in a danger signal enriched microenvir-
onment. As further step towards a better understanding,
we ask whether natural-occurring, autoimmunity-asso-
ciated and tumor-associated antigens have common
structural or biological features and which features differ
between these groups. To this end, we performed a com-
prehensive analysis by compiling data on autoantigens
from our own experimental works and from the litera-
ture. We analyzed common and differential features
using our recently developed GeneTrail [33] analysis tool.
Results
Autoantigens possess in general a longer exon length
We compared the mean exon length of the genes in our
seven test sets with the reference set termed ProteinCo-
dingGenes (PCG) that incorporates all human protein
coding genes excluding the ones contained in the seven
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length (see Table 1), six had also a significantly longer
mean exon length (see Figure 1, left-hand side, row 4 of
the matrix). This astonishing observation seems to be
plausible at the second sight, because genes with longer
exons are transcribed into larger proteins increasing
the probability of the occurrence of potential immuno-
genic features such as mutations, SNPs, immunogenic
sequence patterns and structural epitopes. In addition, a
larger number of exons provides the possibilty of
expressing different splicing products increasing the
probability of confronting the immune system with
untolerized epitopes. However, the differences in exon
length complicate the analysis of these immunogenic
features. To solve this problem, we have defined a sec-
ond reference set called ProteinCodingGenesLongerEx-
ons (PCGLE) that contains all genes in PCG with mean
exon length greater than 3100 nucleotides. The PCGLE
reference set has a mean exon length of 5842 nucleo-
tides that is significantly larger than the mean length of
five test sets (ALL: 4906, CIDB-Serex-AG: 5179, Ex-
Chip-AG: 4355, Lit-AGG: 4710, Lit-PhageDisplay-TAG:
4782) and that does not differ significantly from the
mean of the remaining two small test sets (Exp-Serex-
TAG: 6266, Exp-Serex-HAG: 5986) (see Table 1). When
considering length dependent parameters, we wanted to
exclude an exon length bias and we focussed the discus-
sion here on the results for the five test sets with
s h o r t e rm e a ne x o nl e n g t ht h a ti n v o l v et h el a r g e ra n d
probably more informative test sets. Please note that sig-
nificant results for one of these five test sets and length
dependent features in comparison with the second refer-
ence set reveal a ‘significantly’ stronger density of the
considered features in the test sets. We have chosen this
conservative approach that may lead to the loss of some
signals, because we did not want to carry out the ana-
lyses with different ‘random’ reference sets for the differ-
ent test sets. We carried out all analyses with both
reference sets PCG and PCGLE and compared the two
results whenever we discuss features that may depend
on the mean exon length.
Somatic mutations seem to be more prevalent in TAGs,
SNPs are primarily enriched in AAGs
To test whether our antigen sets have a higher number of
somatic mutations or SNPs compared to the two refer-
ence sets we extracted mutation and SNP data from cur-
rent databases and performed Wilcoxon-Mann-Whitney
t e s t s( W M W ) .A ss o u r c eo fm u t a t i o nd a t aw eu s e dt h e
‘Roche Cancer Genome Database’ (RCGDB) http://rcgdb.
bioinf.uni-sb.de/MutomeWeb/ [34] that combines differ-
ent sources of human mutation databases including the
Catalogue of Somatic Mutations in Cancer (COSMIC),
the Cancer Genome Atlas, and Online Mendelian Inheri-
tance in Man (OMIM). We extracted for each gene in
this database the different types of somatic mutations
and the number of their occurrences in cancer. For the
SNP data we used the dbSNP database from NCBI [35]
as source and extracted the different SNPs for every gene
as deposited. The results of the analyses are summarized
in Figure 1. The heat map on the left-hand side shows
the results for the first reference set PCG and the one on
the right-hand side the results for the second reference
set PCGLE.
When considering SNPs the most obvious enrichment
was found in the set of autoimmune-associated antigens
(Lit-AAG). This enrichment was detected for all SNP
types, including (non)-synonymous SNPs and (non)-
synonymous SNPs normalized. This observation is in line
with published data also reporting an enrichment of
SNPs in autoantigens associated with autoimmune dis-
eases [36]. For tumor antigens, we obtained ambivalent
results. While the test sets CIDB-Serex-AG retrieved
form the CIDB database (Cancer Immunome Database)
and Exp-Serex-TAG identified by SEREX (Serological
Analysis of Recombinant cDNA Expression Libraries)
show an enrichment of SNPs, the set Lit-PhageDisplay-
TAG was not enriched with any type of SNP. For the
Table 1 Data sets for our analyses





CIDB-Serex-AG 1471 5179 http://ludwig-sun5.unil.ch/CancerImmunomeDB/
Exp-Serex-HAG 85 6266 collected by Prof. Meese’s group
Exp-Serex-TAG 74 5986 collected by Prof. Meese’s group
Exp-Chip-AG 298 4355 collected by Prof. Meese’s group
Lit-PhageDisplay-TAG 84 4782 collected by Prof. Meese’s group
Lit-AAG 348 4710 http://www.wiley-vch.de/contents/jc_2040/2005/25481_s.pdf
ALL 2079 4906 union of the above antigen sets
ProteinCodingGenes 23583 3812 all protein coding genes retrieved from NCB1 excluding the above antigens
ProteinCodingGenesLongerExons 8816 5842 corresponds to ProteinCodingGenes with genes having exon lengths >
3100 nucleotides
These data sets are also available online: http://genetrail.bioinf.uni-sb.de/paper/ags/
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with the first reference set PCG, however, compared with
the second reference set PCGLE, we detected an week
enrichment of non-synonymous SNPs (normalized),
which indicates that this set of tumor antigens has a
higher density of non-synonymous SNPs than the refer-
ence set.
For somatic mutations, the results of the different test
sets are also ambivalent. The comparison with the first
reference set PCG indicates that somatic mutations may
play a central role for tumor antigens. However, this ana-
lysis may only reveal the trivial fact that genes with
longer exons may have more (somatic) mutations and
h e n c ed o e sn o tp r o v i d es t r o n ge v i d e n c et h a ts o m a t i c
mutations may induce the humoral immune reactions.
The comparison with the second reference set provides
one remarkable result for the two test sets that have been
collected by literature search. The comparison of the two
sets Lit-AAG and Lit-PhageDisplay indicates that somatic
mutations may play a more crucial role for tumor anti-
gens whereas SNPs may play a more central role for
autoantigens associated with autoimmune diseases. How-
ever, this may be due to the phage display technique that
has been used to identify the tumor antigens.
Autoantigens show in general an enrichment for Granzyme
B cleavage sites, coiled-coil motifs, and ELR motifs
To analyze sequence-based properties of antigens, we
focused on Granzyme B (GrB) cleavage sites [37],
coiled-coils [38], and ELR motifs (Glu-Leu-Arg) [39], all
of which were previously associated with immunogenic
antigens. The analysis with reference PCG shows that
Granzyme B cleavage sites and ELR motifs were
enriched in all data sets. Coiled-coils were also enriched
in all data sets except for tumor antigens identified by
phage display (Lit-PhageDisplay-TAG). These data are
largely in agreement with the idea that these sequence
motifs play a role in the immunogenicity of autoanti-
gens. The comparison with the second reference set
PCGLE confirms these results basically for ELR motifs
and coiled-coils, but not for Granzyme B cleavage sites.
However, it is important to bear in mind that Granzyme
B cleavage sites and coiled-coils are predicted and not
necessarily experimentally proven features. The results
are summarized in the heat maps of Figure 2.
Autoantigens are associated with binding functions
In addition to sequence-based properties, we analyzed
whether certain functional groups, processes or subcellular
Figure 1 Heat maps showing the most frequently enriched somatic mutation and SNP categories and the general exon length in the
considered data sets. Heat maps showing the most frequently enriched somatic mutation and SNP categories and the general exon length in
the considered data sets compared to the ProteinCodingGenes reference set (left-hand side) or compared to the
ProteinCodingGenesLongerExons reference set (right-hand side). ALL: union of all antigen sets; CIDB-Serex-AG: retrieved from the Cancer
Immunome Database (SEREX method); Exp-Chip-AG: mixed antigens (tumor/non-tumor diseases) identified by protein macroarray; Exp-Serex-
HAG: natural occurring autoantigens (SEREX method); Exp-Serex-TAG: tumor antigens (SEREX method); Lit-AAG: autoimmune antigens collected
by literature search; Lit-PhageDisplay-TAG: tumor antigens identified by Phage Display experiments collected by literature search
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his end, we utilized Gene Ontology (GO) [40]. The GO
hierarchy consists of three main categories: molecular
function, cellular component, and biological process. For
the ORA of GO terms, we used only manually curated
GO annotations and not the computationally assigned
annotations (with ‘IEA’ (Inferred from Electronic Annota-
tion) evidence code). Since this analysis yielded more than
200 subcategories that were significant in at least one anti-
gen set, in the following we focus only on the most inter-
esting results for the GO hierarchies molecular function
and cellular component. Most notably, we found in most
antigen sets an enrichment for the category binding and
related categories including protein binding, nucleic acid
binding, and RNA binding. These results provide first evi-
dence that proteins that are part of cellular structures may
show an increased likelihood to become immunogenic.
Lack of enrichment for most of these categories was
observed for the two data sets Exp-Serex-HAG and Exp-
Serex-TAG derived with the SEREX method (Figure 2).
AAGs are often extracellularly localized or get secreted
Another interesting result of the GO analysis showed
that antigens identified in autoimmune diseases (Lit-
AAG) are enriched for GO terms that are not enriched
in other data sets. These GO terms belong to ‘extracel-
lular region/space’, ‘plasma membrane’, ‘vesicle’,a n d
‘secretory granule’. These findings indicate that antigens
of autoimmune diseases have the tendency to get
secreted and/or have an extracellular location where
they might more readily stimulate an immune reaction.
These results are also summarized in Figure 2. Further-
more, antigens identified in autoimmune diseases (Lit-
AAG) are enriched for manycategories related to the
immune system and apoptosis. The complete list of all
222 significantly enriched subcategories is supplied in
Additional file 1 Figure S1. In addition to the GO anno-
tations derived from the ‘cellular component’ hierarchy,
we used the subcellular locations annotated from Uni-
Prot as a second data source to test whether the anti-
gens are enriched in a specific subcellular location [41].
We extracted the corresponding information from the
UniProtKB/Swiss-Prot flatfile ftp://ftp.uniprot.org/pub/
databases/uniprot/current_release/knowledgebase/com-
plete/uniprot_sprot.dat.gz and performed an ORA of all
antigen data sets using the ProteinCodingGenes as refer-
ence. The Lit-AAG set was enriched for the category
‘Secreted’ only. With exception of ‘Exp-Serex-TAG’ all
other antigen sets were enriched for the categories
‘Nucleus’ and ‘Cytoplasm’.
Figure 2 Heat maps showing the significantly enriched motifs, pathways, GO terms and subcellular locations in the considered data
sets. Heat maps showing the significantly enriched motifs, pathways, GO terms and subcellular locations in the considered data sets compared
to the ProteinCodingGenes reference set (left-hand side) or compared to the ProteinCodingGenesLongerExons reference set (right-hand side).
ALL: union of all antigen sets; CIDB-Serex-AG: retrieved from the Cancer Immunome Database (SEREX method); Exp-Chip-AG: mixed antigens
(tumor/non-tumor diseases) identified by protein macroarray; Exp-Serex-HAG: natural occurring autoantigens (SEREX method); Exp-Serex-TAG:
tumor antigens (SEREX method); Lit-AAG: autoimmune antigens collected by literature search; Lit-PhageDisplay-TAG: tumor antigens identified by
Phage Display experiments collected by literature search
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To explore if our antigen sets have certain pathways in
common and if these pathways are involved in immuno-
genic processes, we used the KEGG (Kyoto Encyclopedia
of Genes and Genomes) database, a comprehensive
repository containing regulatory as well as metabolic
pathways [42]. We found enrichment for the subcate-
gories ‘Ribosome’ and ‘Spliceosome’.T h e s er e s u l t sp r o -
vide further evidence that proteins, being part of cellular
structures have a propensity to become immunogenic.
As above, the enrichment of the subcategories Ribosome
and Spliceosome was not found for tumor antigens and
antigens found in healthy persons, both of which were
identified by a SEREX screening. The latter antigen
group also did not show enrichment for any of the path-
way categories. The other antigen groups showed spora-
dic enrichment for a few metabolic pathways and many
regulatory, signal-transduction and cancer pathways (see
Additional file 2 Figure S2). As previously observed,
antigens of autoimmune diseases are different from
other antigen sets in that they show enriched pathways
that are not detected for any other antigen set. These
are pathways of the immune system including ‘Comple-
ment and coagulation cascades’, ‘Antigen processing and
presentation’, ‘Hematopoietic cell lineage’, ‘ECM-recep-
tor interaction’,t h e‘Jak-STAT signaling pathway’,a n d
the autoimmune disease ‘Systemic lupus erythematosus’.
This observation suggests that the occurrence of self-
antigens in autoimmune diseases results from mechan-
isms that are different from the mechanisms occurring
in cancer and in healthy controls.
Molecular mimicry
The molecular mimicry hypothesis implies that an infec-
tious agent elicits an immune response and that a cross-
reaction occurs due to structural resemblance to human
proteins [43-45]. To test the possibility of this hypoth-
esis for the antigens assembled in our sets, we analyzed
t h ep r e v a l e n c eo fp r o t e i ndomains in general and the
occurrence of ancient protein domains. In addition, we
carried out a BLAST analysis of human proteins against
complete sequenced organisms.
No general enriched protein domains, but single
occurrences of Zinc finger and RNA recognition motifs
To search for prevalence of protein domains, we sub-
jected our data sets to an ORA for Gene3D (CATH) and
Pfam domains in a first experiment. CATH is a database
of manually derived structural domains from the Protein
Data Bank (PDB) [46]. These domains are hierarchically
organized according to topology, homology, and conser-
vation [47]. Since CATH annotations are available for a
small number of human proteins, we also used the
CATH domain annotation generated by Gene3D [48].
Here, we extracted the CATH domains deposited in the
Gene3D database v5.2.0. The Pfam database consists of
conserved protein families and domains [49]. We used
Pfam-A, which consists of high quality, manually gener-
ated families. As described previously, we considered
only subcategories (in this case: domains) that appear in
at least 5% of the annotated proteins of a data set to iden-
tify protein domains that occur frequently among anti-
gens. Overall, only a few of several thousand analyzed
domains meet the 5% threshold in our data sets. These
results indicate that domains do not play a general role
in the immunogenicity of antigens. However, we found
evidence for an enrichment of Zinc finger motifs. In
detail, antigens that we identified in tumor and non-
tumor diseases (Exp-Chip-AG) showed enrichment for
protein domains with a Zinc finger motif or an RNA
recognition motif. Normal autoantigens (Exp-SEREX-
HAG) and antigens derived from the Cancer Immunome
Database (CIDB-Serex-AG) are enriched in a CATH
domain named ‘Zinc/RING finger domain’.T h er e s u l t s
are summarized in Figure 3. Since Zinc fingers as DNA-
binding motifs are often found in transcription factors,
these findings are consistent with the notion that pro-
teins, which are part of cellular structures show an
increased likelihood to become immunogenic.
Enrichment of ancient protein domains indicate that
immunogenic proteins are evolutionary conserved
In a second experiment, we analyzed whether our antigen
data sets contain predominantly ‘ancient’ protein families.
To this end, we considered all species of the three king-
doms of life that are contained in the list of completely
sequenced and published genomes from the Genomes
OnLine Database (GOLD) v3.0 http://www.genomeson-
line.org/ and that are annotated with at least 150 protein
domains. We obtained a similar distribution of organisms
for CATH and Pfam domains and on average 450 different
domains per organism. For each kingdom, we extracted all
domains that occur in at least 70% of the species resulting
in three sets of domains (BACTERIA, ARCHAEA,
EUKARYOTA). For each kingdom and the two categories
CATH and Pfam, we mapped the domains to their
corresponding genes resulting in six UNIVERSAL sets
containing genes with ‘ancient’ domains, e.g., UNIVER-
SAL_BACTERIA_CATH. To test the hypothesis whether
our antigen sets are enriched with genes containing
‘ancient’ domains in comparison to our two reference sets,
we performed ORAs for each of the collected UNIVER-
SAL sets. The following antigen sets show an enrichment
of nearly all tested UNIVERSAL classes for the first refer-
ence set: The antigen set that contains all antigens (ALL),
the set derived from the Cancer Immunome Database
(CIDB-Serex-AG), and the set identified by our studies on
tumor and non-tumor diseases (Exp-Chip-AG). Thus, the
analysis of ancient protein domains indicates that immu-
nogenic proteins are evolutionary conserved. The least
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that show vast difference in their genetic makeup not only
in comparison to Eukaryota, but also to Bacteria. Our
results provide no evidence that ancient proteins are speci-
fically enriched in normal autoantigens (Exp-SEREX-
HAG). In summary, evolutionary conservation appears to
be a feature of autoantigens in general. The results of this
analysis are displayed in Figure 4.
Sequence similarities of autoantigens to proteins in other
species support the mimicry hypothesis
As a third test, we explored whether our antigen sets have
more similar sequences in other organisms than the refer-
ence set using the Basic Local Alignment Search Tool
( B L A S T )[ 5 0 ] .B L A S Ti saw e l l - e s t a b l i s h e dm e t h o df o r
finding local sequence similarities of a search pattern a
database of sequences. The BLAST analysis has the
Figure 4 Heat maps summarizing the enriched universal protein domains in the considered data sets.H e a tm a p ss u m m a r i z i n gt h e
enriched universal protein domains in the considered data sets compared to the ProteinCodingGenes reference set (left-hand side) or compared
to the ProteinCodingGenesLongerExons reference set (right-hand side). ALL: union of all antigen sets; CIDB-Serex-AG: retrieved from the Cancer
Immunome Database (SEREX method); Exp-Chip-AG: mixed antigens (tumor/non-tumor diseases) identified by protein macroarray; Exp-Serex-
HAG: natural occurring autoantigens (SEREX method); Exp-Serex-TAG: tumor antigens (SEREX method); Lit-AAG: autoimmune antigens collected
by literature search; Lit-PhageDisplay-TAG: tumor antigens identified by Phage Display-experiments collected by literature search
Figure 3 Heat maps showing the significantly enriched protein domains. Heat maps showing the significantly enriched protein domains
compared to the ProteinCodingGenes reference set (left-hand side) or compared to the ProteinCodingGenesLongerExons reference set (right-
hand side). ALL: union of all antigen sets; CIDB-Serex-AG: retrieved from the Cancer Immunome Database (SEREX method); Exp-Chip-AG: mixed
antigens (tumor/non-tumor diseases) identified by protein macroarray; Exp-Serex-HAG: natural occurring autoantigens (SEREX method); Exp-
Serex-TAG: tumor antigens (SEREX method); Lit-AAG: autoimmune antigens collected by literature search; Lit-PhageDisplay-TAG: tumor antigens
identified by Phage Display experiments collected by literature search
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do not have to involve pre-defined functional domains,
but that may also be candidates for eliciting immune
responses via molecular mimicry. We performed a BLAST
analysis of about 21000 human protein sequences against
the protein sequences from RefSeq release 30 (including
sequences from 5395 different organisms). In brief, we
extracted for each of the human proteins the BLAST hits
that had at least a similarity score of 100 and at most an
E-value of 0.001. To retrieve the information to which
kingdom of life these hits belong, we mapped the hits to
their corresponding organisms. If a human protein had at
least one BLAST hit in a specific organism, we added this
human protein to the hit list of ‘similar’ proteins for this
organism. For excluding hits in not completely sequenced
organisms, we filtered the results using the list of comple-
tely sequenced and published genomes from GOLD. With
the hit lists of ‘similar’ human proteins we performed an
ORA for each organism comparing our antigen sets to our
reference set. In summary, we found 61 of 82 tested
eukaryotes, 437 of 447 organisms of the kingdom Bacteria,
and 39 of 39 tested species from the group Archaea signif-
icantly enriched in at least one of our antigen sets. In the
following, we will briefly discuss the results for the
enriched eukaryotes (Figure 5) and the first reference set
PCG. In analogy to the findings for the universal protein
domains, we observe that the eukaryotic organisms are
predominantly enriched for our data sets. The Exp-Serex-
HAG set shows the lowest number of enriched organisms,
followed by the Lit-AAG, Lit-PhageDisplay-TAG, and
Exp-Serex-TAG set. The remaining sets present almost a
uniform image of enriched organisms. Taking a closer
look at the types of organisms included in Figure 5, we
find well-known representatives of parasites. In addition,
these parasites had most often the lowest p-values for our
different data sets, e.g., Theileria parva strain Muguga,
Theileria annulata strain Ankara, Plasmodium falciparum
3D7, Plasmodium yoelii yoelii str. 17XNL, Cryptospori-
dium parvum Iowa II, Entamoeba histolytica HM-1:IMSS,
Cryptosporidium hominis, and Brugia malayi to mention
Figure 5 Heat maps summarizing the enriched eukaryotic organisms in the considered data sets. Heat maps summarizing the enriched
eukaryotic organisms in the considered data sets compared to the ProteinCodingGenes reference set (left-hand side) or compared to the
ProteinCodingGenesLongerExons reference set (right-hand side). ALL: union of all antigen sets; CIDB-Serex-AG: retrieved from the Cancer
Immunome Database (SEREX method); Exp-Chip-AG: mixed antigens (tumor/non-tumor diseases) identified by protein macroarray; Exp-Serex-
HAG: natural occurring autoantigens (SEREX method); Exp-Serex-TAG: tumor antigens (SEREX method); Lit-AAG: autoimmune antigens collected
by literature search; Lit-PhageDisplay-TAG: tumor antigens identified by Phage Display experiments collected by literature search
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Page 8 of 13the most important of these parasites. Taken together,
these results show that a certain similarity to proteins of
microbes exists and molecular mimicry may play a crucial
role in the immunogenicity of antigens.
Considering the analysis with the second reference set
PCGLE, the two large test sets CIDB-Serex-AG and Ex-
Chip-AG that have also a significantly shorter mean
exon length than the set PCGLE confirm basically the
observations discussed above. However, the results
obtained with the second reference set indicate that
molecular mimicry might play a more important role
for tumor antigens.
Discussion
Multiple reasons may account for the immunogenicity
of antigens including mutations, overexpression [51],
alternative splicing [14,20], expression of fetal proteins
in adult tissue, differential post-translational modifica-
tions, altered processes of apoptosis and necrosis, single
nucleotide polymorphisms (SNPs), specific sequence
motifs, epitope spreading, molecular mimicry, and dif-
ferential cellular localization [12,13]. There is none or
only circumstantial experimental evidence for almost all
of these hypotheses. Likewise, there was virtually no
information whether any of the above listed features can
be preferentially found with a particular group of anti-
gens like natural-occurring, autoimmunity-associated
and tumor-associated antigens.
For most considered antigen sets, we found enrich-
ment of sequence-based properties including coiled-coil
motifs, ELR motifs, and Zinc finger DNA-binding
motifs. Some of these features have been lately proposed
as important for the immunogenicity of autoantigens
such as coiled-coils domains [52] or Granzyme B clea-
vage sites [53]. ELR motifs are supposed to be functional
domains with chemotactic properties that play a role in
CXC chemokines [39]. Since CXC chemokines contain-
ing ELR motifs are important for the activation of leu-
kocytes that take part in phagocytosis of microbes and
foreign antigens they have the ability to activate the
immune system [54]. An overview about motifs impor-
tant for the autoantibody repertoire is given by Plotz
[44]. Although both these previously reported data and
our data provide evidence for a decisive role of sequence
motifs in the immunogenicity of autoantigens, it is
important to bear in mind that some features like clea-
vage sites and the coiled-coils are solely based on pre-
dictions and still await experimental confirmation
[37,38].
Beside sequence-based properties, we found that anti-
gens in our data sets are frequently enriched for the
characteristics of protein binding and DNA or RNA
binding. Many of the immunogenic proteins are also
part of or are associated with ribosomes and
spliceosomes. These results indicate that complex cellu-
lar structures and especially ribosomes are frequently
targets of autoantibodies. This is in keeping with the
particle hypothesis of Tan and Hardin that suggested
that autoantibodies frequently do not target single pro-
teins but cell organelles [55,56]. This hypothesis does,
however, not answer the question why antibodies are
frequently directed against complex cellular structures
like ribosomes. The answer may be provided by another
result of our study showing increased similarity of the
proteins in the antigen sets to proteins of other species.
Due to this increased similarity proteins may have a
higher probability to become immunogenic than pro-
teins that are more specific for human. The reasoning
behind that idea is as follows. The adaptive immune sys-
t e mm u s tb ef l e x i b l ee n o u g ht od e t e c taw i d er a n g eo f
p o s s i b l ep a t h o g e n i ct a r g e t s ,e v e nt h o s et h a ta r es i m i l a r
to self-antigens. However, this flexibility comes with the
risk of autoimmune diseases [57]. In detail, an infectious
a g e n te l i c i t sa ni m m u n er e s p o n s ea n dac r o s s - r e a c t i o n
occurs due to structural resemblance to a human pro-
tein. An example of an infection with a subsequent
cross-reactivity against a self-antigen is the gastric auto-
immunity that is associated with Helicobacter pylori
antigens [58]. Since many of the complex cellular struc-
t u r e sl i k er i b o s o m e sa r ee v o l u t i o n a r yh i g h l yc o n s e r v e d ,
the molecular mimicry hypothesis may explain why
these structures are preferentially targeted by autoanti-
gens. In particular, for ribosomes that often had the
most significant p-values, it is conceivable that their
immunogenicity may be advanced by attached peptides
in statu nascendi (not completely folded or in conforma-
tional transition).
In addition to general features identified for antigens
of our sets, there are some characteristics that appear to
be more specific for single antigen sets. We found evi-
dence for an enrichment of both (non)-synonymous
SNPs and synonymous SNPs in antigens of autoimmune
diseases. Antigens of autoimmune diseases are also
enriched for GO terms ‘extracellular region/space’,
‘plasma membrane part’, ‘vesicle’, and ‘secretory granule’
showing a propensity for secretion and extracellular
location. This may contribute to the stimulation of an
immune reaction. Notably extracellular targets of auto-
antibodies in autoimmune diseases are often directly
linked to the pathogenesis of the disease [59]. In the
majority of cases, it may not be feasible to discern
between a general immunogenic feature and a feature
specific for natural-occurring, autoimmunity-associated
and tumor-associated antigens. Some of the above fea-
tures that are potentially found in all antigens may pre-
ferentially be targeted by autoantibody in the course of
tumor development. Proteins of cancer cells can stimu-
late an immune reaction by necrotic processes or
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Page 9 of 13defective apoptosis. While apoptosis is normally an anti-
inflammatory process with cell debris removed by pha-
gocytic cells, an abnormal apoptosis could lead to APC
(Antigen-Presenting Cell) activation and presentation of
self-antigens. Necrosis is in general a pro-inflammatory
process that occurs during tumor growth exposing the
contents of the cell to the immune system. Proteins
with features identified in this study, e.g. high similarity
to foreign proteins, are likely to be more susceptible to
elicit immune responses in the course of tumor related
processes than proteins without these features.
Interestingly, several of the features identified as pro-
immunogenic in this study, are found with proteins that
are known to play a role in tumor development. A sig-
nificant portion of the immunogenic antigen sets
showed enrichment for Zinc-finger motifs that are often
found in transcription factors. These are frequently
over-expressed in cancer driving the proliferation in
tumor cells. We also found many immunogenic proteins
involved in ribosomes that are discussed to play an
active role in tumorigenesis [60,61]. This finding is in
line with a previous study also reporting that tumor
antigens often play a crucial role in carcinogenesis [13].
Our findings concerning the increased exon lengths of
our antigen sets also support the “stimulation-responsive
splicing” model of Yang et al. [20]. Genes with more
exons can probably create more splice variants by differ-
ent combinations of their exons, which may lead to the
presentation of untolerized epitopes to the immune sys-
tem. In addition, specific sequence features may be
responsible for making those autoantigens more prone
for being processed by the immune system (GrB clea-
vage sites, coiled-coils motifs) or increase the probability
for being recognized as foreign (SNPs, mutations).
A crucial point that influences the results of all per-
formed analyses is the selection of antigen sets that
were used in this work. The properties of the antigen
sets seem to be at least in part dependent on their
experimental technique as indicated by the fact that the
a n t i g e n sd e r i v e df r o mt h eS E R E Xm e t h o da n dt h ep r o -
tein chip often built separate clusters in our analyses.
Furthermore, most of the considered antigens were
detected by few sera only and the mode of detecting
positive antigen-antibody reactions during isolation is
commonly error-prone. Taking these factors into con-
sideration, we were still able to gain new insights in a
highly complex field of research.
Conclusions
Autoantibodies against self-antigens have been asso-
ciated not only with autoimmune diseases, but also with
cancer and are even found in healthy individuals. Whilst
disease associated antigens are already applied as bio-
markers and tumor antigens are studied as putative
vaccines in cancer immunotherapy, the mechanism
causing the autoantibody response and the loss of self-
tolerance remains elusive for the majority of the known
immunogenic antigens. To deepen the understanding of
autoantibody responses, we asked whether natural-
occurring, autoimmunity-associated and tumor-asso-
ciated antigens have structural or biological features in
common. To this end, we have carried out the most
comprehensive in-silicio study of different groups of
autoantigens including large antigen sets identified by
our groups combined with publicly available sets. Our
results indicate that autoimmunogenic proteins are evo-
lutionary conserved and that molecular mimicry might
also play a central role. Taken together, we provided
further indications for differences and similarities in
tumor antigens and autoantigens. However, the picture
that emerged is by far not complete. More effort and
research will be necessary to deepen our understanding
of the immunogenicity of autoantigens.
Methods
Statistical Methods
In order to assess the enrichment of gene sets, we used
the statistical methods integrated in GeneTrail [33]. In
this work, we applied two statistical tests, the so-called
Over-Representation Analysis (ORA) using the hypergeo-
metric distribution test and the Wilcoxon-Mann-Whit-
ney (WMW) test [62]. We applied the ORA in this work
for binary biological categories (e.g. a gene can either
belong to a certain pathway or not). For non-binary cate-
gories (e.g. number of SNPs), we employed the unpaired
one-tailed WMW test to explore if the probability distri-
bution for the values of the test set genes is shifted to the
right of the distribution for the values of the reference set
genes. The computed significance values for both statisti-
cal tests are adjusted by applying the Benjamini-Hoch-
berg approach [63].
Data Sets
The antigen sets used in this work stem either from our
experiments (SEREX, protein arrays), from databases or
from literature search. The different data sets were
named as follows: First, we indicated the source (’Lit’ for
collected from literature, ‘CIDB’ for the Cancer Immu-
nome Database http://ludwig-sun5.unil.ch/CancerImmu-
nomeDB/, ‘Exp’ for our own experimental data), second
the experimental method (e.g. ‘Serex’, ‘Chip’,a n d‘Pha-
geDisplay’), and third the type of antigens contained in
the data set (AG for all antigens, AAG for autoimmune
antigens, HAG for antigens occurring in healthy-per-
sons, TAG for tumor antigens).
The antigen set CIDB-Serex-AG was extracted from
CIDB in February 2009 and contains 1471 antigen
encoding genes. The antigens were originally detected
by SEREX approach in various cancers [64]. The
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Page 10 of 13sequences and identities were deposited in the CIDB
database.
The antigen sets Exp-Serex-HAG and Exp-Serex-TAG
were derived from our experiments also using SEREX.
Exp-Serex-HAG contains 86 known genes that were
detected with sera of healthy persons, and Exp-Serex-
TAG contains 74 antigens that were reactive with sera
of different cancer patients including patients with
meningioma, glioma or lung cancer [7,8,65].
We also identified the set Exp-Chip-AG containing
298 antigens using a protein macroarray that contained
proteins derived from a recombinant human fetal brain
library [66]. The library that contained 38,000 E. coli
clones was screened with 30 serum pools of patients
with different tumor and non tumor diseases including
prostate cancer, lung cancer, meningioma, glioma, wilms
tumor, neuroblastoma, morbus crohn, colitis ulcerosa,
stroke and benign prostate hyperplasia and healthy con-
trols [9,10,67,68]. All antigens that were positive for at
least one serum pool were included in our analysis.
Two data sets were derived from literature search. The
Lit-PhageDisplay-TAG set contains 84 tumor antigens
that were isolated with theP h a g eD i s p l a yl i b r a r y
method. The antigen set Lit-AAG that is online avail-
able contains 348 genes associated with autoimmune
diseases http://www.wiley-vch.de/contents/jc_2040/2005/
25481_s.pdf. This set was initially collected to analyze
the occurrences of SNPs (single nucleotide polymorph-
isms) in autoantigens [36].
The ALL set contains the union of all antigens of the
data sets Lit-AAG, Exp-Serex-HAG, Exp-Chip-AG, Exp-
Serex-TAG, CIDB-Serex-AG, and Lit-PhageDisplay-
TAG. This set is to find patterns prevalent to all
antigens.
As first reference set - termed ProteinCodingGenes -,
we used all human protein coding genes excluding the
above-mentioned antigens (human protein coding genes
minus genes in the ALL set). In order to exclude a bias
that could be introduced by the exon lengths of the
genes in the sets, we performed the analyses with a sec-
ond reference set - termed ProteinCodingGenesLonger-
Exons - that consists of the genes of the first reference
set whose exon lengths were larger than 3100 nucleo-
tides. This results in a reference set that contains genes
having significantly larger exon lengths or do not differ
significantly when compared to the different antigen
sets. The different data sets are summarized in Table 1.
Some representative examples of autoantigens found in
our data sets are listed in Table 2.
If not mentioned otherwise we performed the analyses
for all antigen sets using GeneTrail [33] with the follow-
ing parameters: significance level: 0.05; minimum num-
ber of genes in a subcategory: 2; p-value computation:
FDR correction; reference set: ProteinCodingGenes.
When performing an Over-Representation Analysis
(ORA), we filtered the results afterwards for significantly
enriched subcategories where at least 5% of the genes of
the test set had an annotation for the considered cate-
gory. Hereby, we focused on subcategories that show
prevalence in our antigen sets.
Additional material
Additional file 1: Figure S1: Overview of all significant GO
categories. Heat maps showing the significantly enriched GO terms in
the considered data sets compared to the ProteinCodingGenes reference
set (left-hand side) or compared to the ProteinCodingGenesLongerExons
reference set (right-hand side). ALL: union of all antigen sets; CIDB-Serex-
AG: retrieved from the Cancer Immunome Database (SEREX method);
Exp-Chip-AG: mixed antigens (tumor/non-tumor diseases) identified by
protein macroarray; Exp-Serex-HAG: natural occurring autoantigens
(SEREX method); Exp-Serex-TAG: tumor antigens (SEREX method); Lit-
AAG: autoimmune antigens collected by literature search; Lit-
PhageDisplay-TAG: tumor antigens identified by Phage Display
experiments collected by literature search.
Additional file 2: Figure S2: Overview of all significant KEGG
categories. Heat maps showing the significantly enriched KEGG
pathways in the considered data sets compared to the
ProteinCodingGenes reference set (left-hand side) or compared to the
ProteinCodingGenesLongerExons reference set (right-hand side). ALL:
union of all antigen sets; CIDB-Serex-AG: retrieved from the Cancer
Immunome Database (SEREX method); Exp-Chip-AG: mixed antigens
(tumor/non-tumor diseases) identified by protein macroarray; Exp-Serex-
HAG: natural occurring autoantigens (SEREX method); Exp-Serex-TAG:
tumor antigens (SEREX method); Lit-AAG: autoimmune antigens collected
by literature search; Lit-PhageDisplay-TAG: tumor antigens identified by
Phage Display experiments collected by literature search.
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